US Patent 10913722 Compositions and methods of treating retinal disease
Patent 10913722 was granted and assigned to Aldeyra Therapeutics on February, 2021 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
January 7, 2019
Date of Patent
February 9, 2021
Patent Applicant
Patent Application Number
16241851
Patent Citations Received
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 10913722 Compositions and methods of treating retinal disease
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
